TLDR
- Olema Pharmaceuticals (OLMA) advanced 8.5% Monday following fourth-quarter results that surpassed EPS forecasts, posting a loss of $0.50 versus the anticipated $0.51.
- Fourth-quarter GAAP net loss reached $46.1 million, while the full-year 2025 loss totaled $162.5 million.
- Stifel maintained its Buy rating alongside a $48 price target after the release, highlighting cash reserves extending through mid-2028.
- Roche’s persevERA trial recently failed to achieve its primary endpoint, potentially influencing perspectives on Olema’s OPERA-02 trial trajectory.
- Wall Street consensus reflects a “Moderate Buy” stance with a $41 average price target, while shares have declined 41% year-to-date following a 234% surge over the prior year.
Olema Pharmaceuticals (OLMA) registered an 8.5% gain Monday after delivering fourth-quarter financial results that exceeded analyst projections. Shares reached an intraday peak of $16.07 before closing near $15.96, advancing from the previous session’s $14.71 finish.
Olema Pharmaceuticals, Inc., OLMA
The biotechnology company recorded a per-share loss of $0.50 for the fourth quarter of 2025, surpassing the Wall Street consensus forecast of ($0.51) by one cent. While the margin was modest, it provided sufficient momentum for share appreciation.
Across the entire 2025 fiscal year, Olema recorded a GAAP net loss totaling $162.5 million. The fourth quarter alone contributed $46.1 million to that figure. Management elected to skip an earnings conference call following the release.
The stock has experienced significant volatility despite sustained losses. OLMA has delivered a 234% return over the trailing twelve months, yet has surrendered 41% of its value year-to-date through Monday’s pre-market session.
Monday’s session volume registered 518,220 shares — substantially below the typical daily average of approximately 1.6 million. The reduced activity level may signal investor hesitation rather than strong buying conviction.
Analyst Reaction
Stifel responded immediately to the quarterly release, confirming its Buy rating while maintaining the $48 price target. The investment firm emphasized Olema’s financial resources extending into mid-2028 as a significant advantage, providing coverage for multiple developmental milestones ahead of palazestrant’s anticipated market entry.
Palazestrant targets second- and third-line metastatic breast cancer treatment, with commercial availability projected for 2027.
Wall Street sentiment remains generally favorable. Ten analysts maintain Buy ratings on shares, while one holds a Hold recommendation and one carries a Sell stance. The consensus price target stands at $41.00 — representing substantial upside from current trading levels.
Oppenheimer reaffirmed its Outperform stance on March 9th. JPMorgan elevated its target from $29 to $32 in November while maintaining an Overweight rating. TD Cowen continues with a Buy recommendation, suggesting palazestrant offers superior exposure compared to alternative therapies.
H.C. Wainwright reduced its target to $38 while preserving its Buy rating after recent clinical trial developments.
The Roche Factor
Earlier this month, Roche disclosed that its persevERA clinical trial — assessing giredestrant combined with palbociclib for first-line metastatic breast cancer — failed to achieve statistical significance for its progression-free survival primary endpoint. While a favorable numerical trend emerged, the statistical miss carries weight.
The persevERA results are commonly interpreted as a potential indicator for Olema’s Phase 3 OPERA-02 study, which evaluates palazestrant. Top-line readouts from OPERA-02 remain on track for at least 2028 or beyond.
Stifel noted that Roche’s comprehensive persevERA dataset will probably be unveiled at ASCO 2026, potentially serving as the next significant catalyst — or challenge — for OLMA shares.
Regarding financial positioning, Olema maintains greater cash holdings than outstanding debt, reflected in a current ratio of 8.03. The 50-day moving average rests at $24.18, considerably above Monday’s price action.
Institutional ownership comprises 91.78% of outstanding shares. Company insiders have engaged in net selling activity — disposing of approximately 805,501 units valued at roughly $23 million during the past three months.
The company’s market capitalization currently stands near $1.09 billion.
